In general, if the atoms that make up the ring contain heteroatoms, such rings become heterocycles, and organic compounds containing heterocycles are called heterocyclic compounds. An article called Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789), published in 2012-05-24, which mentions a compound: 91912-53-7, Name is 3-(Pyridin-4-yl)-1H-pyrazol-5-amine, Molecular C8H8N4, Application In Synthesis of 3-(Pyridin-4-yl)-1H-pyrazol-5-amine.
Alpha-7 nicotinic acetylcholine receptors (α7 nAChR) are implicated in the modulation of many cognitive functions such as attention, working memory, and episodic memory. For this reason, α7 nAChR agonists represent promising therapeutic candidates for the treatment of cognitive impairment associated with Alzheimer’s disease (AD) and schizophrenia. A medicinal chem. effort, around our previously reported chem. series, permitted the discovery of a novel class of α7 nAChR agonists with improved selectivity, in particular against the α3 receptor subtype and better ADME profile. The exploration of this series led to the identification of 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide [(I), SEN15924, WAY-361789], a novel, full agonist of the α7 nAChR that was evaluated in vitro and in vivo. Compound I proved to be potent and selective, and it demonstrated a fair pharmacokinetic profile accompanied by efficacy in rodent behavioral cognition models (novel object recognition and auditory sensory gating).
In addition to the literature in the link below, there is a lot of literature about this compound(3-(Pyridin-4-yl)-1H-pyrazol-5-amine)Application In Synthesis of 3-(Pyridin-4-yl)-1H-pyrazol-5-amine, illustrating the importance and wide applicability of this compound(91912-53-7).